What exactly changed in the Craig-Hallum note on March 06, 2026?

Craig-Hallum maintained its **Buy** rating and raised the price target to **$16** from **$15**. The note cited stronger Q4 revenue and improved adjusted EBITDA as reasons for the modest increase in valuation. The BVS analyst rating stayed Buy.

How should investors interpret the BVS analyst rating of Buy with a $16 target?

A Buy with a **$16** target signals analyst confidence in growth and margins, but it is a modest upgrade. Investors should weigh the BVS analyst rating against company guidance, competitive risk, and execution timelines before acting.

Does the Craig-Hallum change mean the stock will rise immediately?

Not necessarily. Craig-Hallum’s maintained Buy and higher price target raise the case for upside, but the market can react differently short term. Monitor earnings, guidance execution, and new analyst notes alongside the BVS analyst rating.

Analyst Ratings

Craig-Hallum Maintains Buy on Bioventus Inc (BVS) March 2026, PT $16

ByHuzaifa Zahoor March 7, 2026March 7, 2026

Craig-Hallum maintained a Buy rating on Bioventus Inc. (BVS) on March 06, 2026, and raised its price target to $16. The note followed a stronger-than-expected fourth quarter and updated 2026 guidance. The BVS analyst rating update is notable because it keeps conviction while nudging upside expectations higher. Meyka AI rates BVS with a grade of B+. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. At the time of the note the stock moved -0.83% ($-0.07) and market capitalization stood at $563,272,172. For full coverage see the Craig-Hallum write-up and industry summaries StreetInsider and broader analyst notes Investing.com.